Results 121 to 130 of about 2,201,777 (199)

P76.18 Tissue- and Plasma-Based Landscape of Resistance to Osimertinib [PDF]

Journal of Thoracic Oncology, 2021
S.M. Lim, S. Yang, S.B. Lim, S.G. Heo, S. Daniel, A. Markovets, M. Rafati, C. Park, J. Yun, K. Pyo, M.R. Yun, B. Ahn, M.H. Hong, H.R. Kim, B.C. Cho   +14 more
openaire   +1 more source

TPD52L1-ROS1 Rearrangement as a New Acquired Resistance Mechanism to Osimertinib That Responds to Crizotinib in Combination With Osimertinib in Lung Adenocarcinoma [PDF]

JTO Clinical and Research Reports, 2020
Caihua Xu, MD, Dapeng Li, MD, Weiming Duan, MD, Min Tao, PhD   +3 more
openaire   +3 more sources

Possibilities of Liquid Biopsy in Determining the Mechanisms of Resistance to Osimertinib

Voprosy onkologii
Цель. Выявление механизмов резистентности к осимертинибу в циркулирующей опухолевой ДНК (цоДНК). Материалы и методы. В рамках исследования Trust (многоцентровое неинтервенционное ретро- и проспективное исследование безопасности и эффективности применения осимертиниба в рамках Программы раннего доступа (EAP) и реальной клинической практики у пациентов с
openaire   +1 more source

A fungal-derived benzothiazole derivative overcomes osimertinib resistance in NSCLC by targeting SCD1. [PDF]

Nat Prod Bioprospect
Li B, Ke Y, Zhu J, Zhang W, Yang M, Li Z, Chen M, Liu Z, Liu J, Deng Q, Zhang P, Lei X.   +11 more
europepmc   +1 more source

P1.14-16 Resolving Resistance to Osimertinib by Combining Apatinib and Osimertinib in EGFR-Mutant NSCLC Patients [PDF]

Journal of Thoracic Oncology, 2019
X. Yang, J. Zhao, L. Liang, L. Xu
openaire   +1 more source

Development of a structurally distinct TopBP1 inhibitor that enhances PARP blockade and reverses osimertinib resistance. [PDF]

Sci Adv
Lin FT, Lin SJ, Liu K, Xiao Y, Wilhelms Garan LA, Folly-Kossi H, Lin WC.   +6 more
europepmc   +1 more source

Osimertinib Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Mechanisms and Therapeutic Strategies. [PDF]

MedComm (2020)
Guo J, Wen Q, Fan S.
europepmc   +1 more source

Inhibition of ferroptosis via SLC25A39-NRF2 axis drives Osimertinib resistance in lung adenocarcinoma. [PDF]

Cell Mol Life Sci
Fu K, Zeng Z, Wang W, Wu W, Gong Y, Fu X, Cai Y, Liu C.   +7 more
europepmc   +1 more source

Altered Sphingolipid Metabolism is Associated with Osimertinib Resistance in Nonsmall-Cell Lung Cancer. [PDF]

J Proteome Res
Babuta J, Gruevska A, Wickremesinghe C, Montoya A, Roumelioti G, Shliaha P, Balcells C, McKinney F, Bray C, Athersuch T, Martin M, Keun H, Hall Z.   +12 more
europepmc   +1 more source

Adaptive Regulation of dNTP Homeostasis Confers Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Carcinoma. [PDF]

Cancer Res
Xie Q, Wang Y, Fernandez A, Lei Y, Gong Y, Hess JD, Yang L, Xin D, Williams TM, Zheng L, Shen B, Li M.   +11 more
europepmc   +1 more source